Showing results (331-340 of 380) with videos related to
Sort By:
Pageof 38
Cancers|June 2, 2021
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg StudyHenner Stege, Maximilian Haist, Michael Schultheis, et al.European Journal of Cancer (Oxford, England : 1990)|July 24, 2023
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyGeorg C Lodde, Jessica Hassel, Lena M Wulfken, et al.European Journal of Cancer (Oxford, England : 1990)|February 26, 2026
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREGKonstantinos Lallas, Lena Nanz, Selma Ugurel, et al.European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomasPhilipp Jansen, Wolfgang Galetzka, Georg C Lodde, et al.European Journal of Cancer (Oxford, England : 1990)|May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGAnne Zaremba, Peter Mohr, Ralf Gutzmer, et al.Journal of Cancer Research and Clinical Oncology|November 21, 2020
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)Theresa Steeb, Anja Wessely, Mareike Alter, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibJan C Brase, Robert F H Walter, Alexander Savchenko, et al.European Journal of Cancer (Oxford, England : 1990)|December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyCarl M Thielmann, Johanna Matull, Anne Zaremba, et al.European Journal of Cancer (Oxford, England : 1990)|February 11, 2023
Characterisation and outcome of RAC1 mutated melanomaGeorg C Lodde, Philipp Jansen, Rudolf Herbst, et al.Nature Cancer|June 17, 2022
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapyThomas Walle, Sunanjay Bajaj, Joscha A Kraske, et al.Pageof 38